GeNeuro 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases  1 Product   1 Trial   109 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
temelimab (GNbAC1) / GeNeuro
2021-001973-21: Extension of Study GNC-401 with temelimab in patients with Multiple Sclerosis under treatment with rituximab

Not yet recruiting
2
40
Europe
Temelimab, GNbAC1, Solution for infusion
GeNeuro Innovation SAS, GeNeuro Innovation SAS
Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
2019-004822-15: A Clinical Trial Examining the Effects of Temelimab Following Rituximab Treatment in Patients with Multiple Sclerosis

Not yet recruiting
2
40
Europe
Temelimab, GNbAC1, Solution for infusion
GeNeuro Innovation SAS, GeNeuro Innovation SAS
Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
2022-000618-32: A research study to find out if Temelimab is safe and efficacious to treat neuropsychiatric symptoms in post-COVID-19 Uno studio di ricerca per scoprire se Temelimab รจ sicuro ed efficace nel trattattamento dei sintomi neuropsichiatrici nel post-COVID-19

Not yet recruiting
2
200
Europe
Temelimab, [GNbAC1], Solution for infusion
GENEURO SA, GeNeuro S.A., GeNeuro S.A.
Postacute Sequelae of COVID-19 (PASC) Syndrome Sindrome post-COVID-19 o con sequele post-acute da COVID-19 (PASC), Postacute Sequelae of COVID-19 (PASC) Syndrome Sindrome post-COVID-19 o con sequele post-acute da COVID-19 (PASC), Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05497089 / 2022-000618-32: Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome

Completed
2
203
Europe
Temelimab 54mg/kg, Placebo
GeNeuro SA, GeNeuro S.A.
Post-COVID-19 Syndrome
05/24
05/24
GNK301 / GeNeuro
No trials found

Download Options